Hansoh Pharma psoriasis drug meets Phase 3 trial endpoints

Hansoh Pharma reported positive results from a pivotal Phase 3 trial for its psoriasis drug HS-10374 in adults with moderate-to-severe plaque psoriasis. The study met its primary endpoints, showing clear clinical improvement compared to placebo and supporting a favorable benefit-risk profile within the TYK2 class. The company plans to present detailed results at a future dermatology congress and initiate regulatory discussions in China to support a New Drug Application.